Gout
Conditions
Interventions
Urate-lowering therapy group:Febuxostat 20~80 mg/day or benzbromarone 25~50 mg/day while without anti-hypertension drugs
Control group:Without urate-lowering therapy while without anti-hypertension drugs
Sponsors
the Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 30 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 - 30 years, male, meet the clinical classification and diagnosis criteria of gout of 2015 ACR / ELUAR; 2. Patients with serum uric acid value >= 360 umol/L; 3. Obtain the consent of the subject, or family member, or guardian, or legal representative and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic or contraindicated to all drugs or ingredients in the test, or those who are allergic to or have high sensitivity constitution; 2. The patients who had acute gouty arthritis attack in the first two weeks of randomization; 3. Patients who used antiduricemic drugs within 2 weeks before randomization; 4. Glucocorticoids, antituberculosis drugs (such as ethambutol, pyrazinamide), anticoagulants (such as warfarin or other coumarin anticoagulants, bivalirudin), immunosuppressants (such as cyclosporin, tacrolimus), aspirin or other salicylic acid substances, azathioprine, 6-mercaptopurine, cyclophosphamide, sulfamethoxate, oxazole, trimethoprim, theophylline, niacin, estrogen and other drugs that affect the metabolism of uric acid were used or planned to be used within the first two weeks of randomization; 5. Patients with active peptic ulcer, abnormal thyroid function, malignant tumor, active tuberculosis and urinary calculi; 6. Patients with rheumatoid arthritis, rheumatoid arthritis, arthritis caused by other rheumatic immune diseases, or osteoarthritis requiring analgesic treatment; 7. Patients with heart failure with limited activity (previously confirmed, or with clinical manifestations of heart failure, confirmed after consultation with cardiology department), unstable angina pectoris, previous history of myocardial infarction within 12 months or other patients with serious heart disease; 8. Patients with secondary hyperuricemia caused by hematopathy, malignant tumor, kidney disease or tumor radiotherapy and chemotherapy; 9. Patients with renal insufficiency; 10. Patients with active liver disease or cirrhosis, or abnormal liver function [patients with serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >= 1.5 ULN or TBIL >= 1.5 ULN; 11. Patients with severe hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg) who were not effectively controlled after treatment; 12. Patients who are receiving or do not receive hypoglycemic drugs but HbA1c > 8%; 13. Leukocyte count < 3.5x10^9/L, platelet < 100x10^9/L, hemoglobin < 90 g/L; 14. Patients with brain diseases, abnormal judgment ability and uncooperative mental disorders; 15. Patients who have a history of drinking or taking illegal drugs; 16. Patients who have participated in other clinical trials within three months before the screening of this trial; 17. Patients considered unsuitable by other researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum uric acid;Systolic blood pressure;Diastolic blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Height;Weight;Alanine aminotransferase;Aspartate aminotransferase;Total cholesterol;Triglycerides;Fasting plasma glucose;Serum creatinine;Fatty liver;Kidney stones;Tophus; | — |
Countries
China
Contacts
Public ContactChanggui Li
the Affiliated Hospital of Qingdao University
Outcome results
None listed